A Patient Died in a Schizophrenia Trial. Now the FDA Wants Answers.

The idea is to use evenamide as an add-on to existing antipsychotics for patients with treatment-resistant schizophrenia (TRS): people whose symptoms don't respond adequately to standard drugs. These are among the hardest patients to help in all of psychiatry.

The Damage Report

The hold applies only to U.S. sites. That's an important distinction. Enrollment continues in India, Argentina, and at sites nearing activation in Colombia and Malaysia. ENIGMA-TRS 1, a separate Phase 3 trial running in Europe, Canada, Latin America, and Asia, remains completely unaffected.

Still, this is a meaningful setback. ENIGMA-TRS 2 aims to enroll roughly 400 patients total. Losing your U.S. sites (including UCLA's Semel Translational Research Center, the first activated American location) slows recruitment and raises questions with investors. Newron's stock has been volatile; shares have ranged from a 52-week low of CHF 5.20 to a high of CHF 31.85, trading recently around CHF 21.40.

The company says it still expects 12-week primary endpoint results in Q4 2026. Whether the hold delays that timeline depends entirely on how quickly Newron can satisfy the FDA's concerns.

CNS Trials: Where Good Programs Go to Struggle

Newron isn't the first company to hit this wall. In 2024, Neumora Therapeutics saw its schizophrenia candidate NMRA-266 placed on clinical hold after preclinical data showed convulsions in rabbits.

Developing drugs for the brain is notoriously brutal. The organ is complex, protected by the blood-brain barrier, and the diseases it develops are poorly understood at a molecular level. Clinical holds, failed trials, and unexpected safety signals are almost a rite of passage in CNS drug development.

Boehringer Ingelheim's iclepertin failed its Phase 3 in late 2024. Neumora had to pivot its entire schizophrenia franchise. The graveyard of abandoned brain drugs could fill a textbook.

A Crowded (and Fragile) Race

Evenamide isn't competing in a vacuum. The schizophrenia pipeline has gotten more interesting in the past two years, with several novel mechanisms advancing:

• KarXT (Bristol Myers Squibb) became the first non-dopaminergic antipsychotic approved in 2024, working through muscarinic receptors.
• LB-102 (LB Pharmaceuticals) completed Phase 2 and is heading toward Phase 3.
• Ulotaront (Sumitomo Pharma) targets the TAAR1 receptor, another non-dopamine approach.
• Multiple M4 muscarinic modulators (Neumora, NeuShen) are in early-to-mid stage development.

Evenamide's glutamate-based mechanism is genuinely different from all of these. If it works, it could offer something unique for treatment-resistant patients. But "if" is doing a lot of heavy lifting in that sentence right now.

What Happens Next

Newron needs to respond to the FDA with enough safety data to demonstrate that evenamide didn't cause this death and that the risk-benefit profile remains acceptable. Clinical holds can be lifted in weeks or drag on for months, depending on the complexity of the agency's questions and the quality of the company's data package.

The independent safety board's recommendation to continue is a good sign. No increased mortality has been observed between evenamide and placebo groups across the program so far. But the FDA operates on its own timeline, with its own standards.

For Newron, the math is simple: resolve this quickly, keep international enrollment on track, and hit that Q4 2026 data readout. For the roughly 30% of schizophrenia patients who don't respond to existing treatments, the stakes are even simpler. They're running out of options, and they need this science to work.

The hold is a speed bump, not necessarily a dead end. But in CNS drug development, speed bumps have a way of becoming sinkholes. We'll be watching.

GSK Bet $700M on a Brain Theory. It Just Lost Twice.

GSK and Alector just killed their second Alzheimer's trial in six months, effectively torching a $700 million partnership. The failure raises uncomfortable questions about whether targeting the brain's immune system can actually slow neurodegeneration.